Childhood acute lymphoblastic leukaemia is frequently initiated prenatally with a subsequent latent period of several years. 1 The most common subtype (20% of all cases) harbours the t(12;21)(p13;q22)[ETV6-RUNX1] translocation. 2 Clone-specific ETV6-RUNX1 fusion primers have allowed the mapping of parts of the natural history of this acute lymphoblastic leukaemia subset, including back tracking to the neonatal period. 3, 4 Although other markers have been used, the ETV6-RUNX1 translocation remains paramount in studies of the natural history of common childhood acute lymphoblastic leukaemia because of its relatively high incidence and its leukaemia specificity as opposed to, for example, antigen receptor markers. 5 The clonespecific ETV6-RUNX1 break points have mainly been identified by multiplex PCR or by long-distance inverse PCR techniques. 3, 4, 6, 7 However, because of the insufficient quantity and quality of diagnostic DNA and the spread of potential break points over almost 200 kb, these approaches may frequently fail, and thus hamper the exploration of ETV6-RUNX1-positive cases.
Whole-genome amplification (WGA) methods have been developed to overcome the quantity of DNA as a limiting factor in molecular genetics. Accordingly, we explored the usefulness of WGA in combination with a multiple tiling PCR setup on three potential DNA sources for the identification of ETV6-RUNX1 chromosomal break points.
Six ETV6-RUNX1-positive cases, for which we had been unable to map the chromosomal break points of the translocation by conventional multiplex PCR or long-distance inverse PCR were selected for this study. The archival sources of DNA were the following: (A) Genomic DNA from mononuclear cells isolated by Ficoll density centrifugation from peripheral blood or bone marrow, purified using a standard SDS/proteinase K/phenol extraction method at the time of diagnosis. (B) Glass slides with alcohol-fixated, May-Grü nwald-Giemsa-stained diagnostic bone marrow aspirate smears. The cells were scraped off the slides, and DNA was extracted using NucleoSpin Tissue Protocol (Macherey-Nagel, Dü ren, Germany), yielding on an average 100 ng DNA per slide. (C) Finally, DNA from formalinfixed, paraffin-embedded (FFPE) material was extracted essentially as described earlier 8 from three 50 mm section cuts. The DNA yield was between 2 and 10 ng.
DNA was amplified using the Repli-g Midi Kit (Qiagen, Hilden, Germany) following the manufacturer's recommendations and was subsequently purified using the QIAamp DNA mini kit (Qiagen). When using DNA from fresh bone marrow samples or glass slide DNA, a 10 ng input gave on an average 18 mg amplified DNA as estimated by A 260 and A 280 OD readings (NanoDrop, Thermo Scientific, Waltham, MA, USA). The presence of high-molecular-weight DNA, that is, fragments 410 kb in length, was verified on 2% argarose gel. FFPE-DNA amplified considerably less (up to 100 Â per run) and fragments larger than 1 kb were not observed.
To identify the exact ETV6 and RUNX1 chromosomal break points, a multiple tiling PCR setup was designed: 15 upstream primers covering the 15 kb of intronic DNA between exons 5 and 6 in ETV6 on chromosome 12 were designed with an interprimer distance of 1 kb. Similarly, 160 downstream primers were spaced within the 162 kb region between exons 1 and 3 in RUNX1 on chromosome 21. Primers were designed using Primer3 Software (http://frodo.wi.mit.edu/), with an annealing temperature of 60±0.5 1C. To reduce hands-on time, a BioMEKFX robot (Beckman-Coulter, Fullerton, CA, USA) was used for the PCR setup in 384-microwell PCR-plates. PCR was performed in 5 ml reactions with a 10 ng WGA-DNA template using Platinum TaqPolymerase (Invitrogen, Carlsbad, CA, USA) in a standard setup. To minimize false-positive amplification, a 'touch-down PCR' protocol was used: initial denaturation at 94 1C for 1 min was followed by five cycles of 15 s at 94 1C, 30 s at 65 1C and 2 min at 70 1C. Another five cycles were carried out at an annealing temperature of 62 1C, followed by 30 cycles at an annealing temperature of 60 1C. Products were visualized on 2% argarose gel. As the theoretical distance between primers spanning the break point was o10-2000 bp and Platinum TaqPolymerase amplifies sequences of 4 kb or more, several true-positive products of increasing length could be found (Figure 1) . Thus, although some of the primer combinations gave rise to false-positive results, the tiling PCR setup allowed the easy identification of true-positive results by the positivity of flanking reactions, with PCR products being 1000 bp longer or shorter. This also allows a significant reduction in the number of primer combinations needed to be tested by including only every third ETV6 primer in the initial screening. Positive tubes are then explored by running their flanking primer combinations. Positive reactions (that is, those confirmed by their positive flanking primer combinations) were sequenced using BigDye Terminator v3.1 sequencing chemistry on a 3100 Genetic Analyzer according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA).
The ETV6-RUNX1 fusion break points were identified in all six cases, when WGA-DNA from fresh bone marrow samples or glass slides was used. In contrast, amplified DNA from FFPE material (n ¼ 5) yielded insufficient quantities and qualities of DNA. Thus, although the presence of the ETV6-RUNX1 chimeric region could be confirmed, when using closely flanking, break-point-specific primers, the multiple tiling PCR setup failed to identify break points. The inability to achieve PCR products 41000 bp means that break-pointspanning reactions may be lacking, and true and false reactions cannot be distinguished because of the lack of a positive flanking reaction. This reflects the DNA degradation caused by formalin, which is consistent with earlier findings 8 . Thus, the need for a relatively high-molecular-weight DNA to identify specific t(12;21) break points makes FFPE material a poor source of DNA for break-point identification.
In conclusion, WGA on sparse or moderately degenerated leukaemic DNA (including from glass slides) yields large quantities of DNA, which allows the identification of the clonespecific ETV6-RUNX1 fusion sequence using a multiple tiling PCR setup. This should allow the identification of individual ETV6-RUNX1 break points in virtually all patients in future studies on the natural history of ETV6-RUNX1-positive acute lymphoblastic leukaemia.
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The authors declare no conflict of interest. Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous but aggressive disease in which cytogenetic findings are considered to be the most powerful single prognostic factor. 1 Most patients belong to the category with standard-risk disease and the stratification of this heterogeneous group seems to be insufficient. Along with cytogenetics, mutational analysis is one of the most important approaches to gain understanding of the molecular bases of leukemogenesis. Dash and Gilliland 2 suggested that AML blasts develop from normal blasts affected by two types of genetic damage: class I and class II mutations. Class I mutations result in constitutive activation of cell surface receptors and confer a proliferative and survival advantage on the blast cells. This group includes activating mutations in receptor tyrosine kinases such as FLT3 (fms-like tyrosine kinase-3) and c-KIT and in the GTPase RAS family. In contrast, class II mutations seem to impair differentiation, but are not sufficient to cause leukemia when expressed alone. This second group includes chromosomal rearrangements leading to AML1-ETO, CBFb-MYH11 or MLL fusion genes, deregulation of HOX genes expression and mutations in CEBPa (CCAAT/enhancer-binding protein a) gene. More recently, gene mutations in two new molecular markers, NPM1 (nucleophosmin) and WT1 (Wilms' tumor 1), were reported to have a critical function in leukemia. The two-hit model of leukemogenesis, combining an activating lesion of tyrosine kinase pathways with event-blocking myeloid differentiation, seems very interesting to screen molecular events in AML patients, in view of the frequent association of a class I and a class II mutation.
There exist many studies of the frequency and prognostic significance of gene mutations in adult AML. Very few studies have been performed in pediatric populations. We studied a well-characterized cohort of 76 children with de novo AML and evaluated at diagnosis the frequency and the impact on clinical outcome of FLT3 internal tandem duplication (FLT3-ITD) and tyrosine kinase domain (FLT3-TKD), c-KIT, N-RAS, K-RAS, CEBPa, NPM1 and WT1 gene mutations in pediatric AML with a long clinical follow-up (median, 72 months). The main aim of the study was to determine whether these molecular lesions could be used to improve the molecular-risk stratification to better predict the response to therapy.
In 76 children diagnosed with de novo AML, we found FLT3-ITD, FLT3-TKD, c-KIT, N-RAS, K-RAS, CEBPa, NPM1 and WT1 
